CJ-042794 (CJ-042794) is a a novel, potent, and selective prostaglandin EP(4) receptor antagonist, with a mean pKi of 8.5, a binding affinity that was at least 200-fold more selective for the human EP4 receptor than other human EP receptor subtypes (EP1, EP2, and EP3).

Physicochemical Properties

Molecular Formula	C22H17CLFNO4
Molecular Weight	413.8261
Exact Mass	413.083
Elemental Analysis	C, 63.85; H, 4.14; Cl, 8.57; F, 4.59; N, 3.38; O, 15.46
CAS #	847728-01-2
PubChem CID	11524454
Appearance	White to off-white solid powder
Density	1.3±0.1 g/cm3
Boiling Point	572.7±50.0 °C at 760 mmHg
Flash Point	300.2±30.1 °C
Vapour Pressure	0.0±1.7 mmHg at 25°C
Index of Refraction	1.616
LogP	5.91
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	6
Heavy Atom Count	29
Complexity	561
Defined Atom Stereocenter Count	1
SMILES	O(C1C=CC(F)=CC=1)C1=CC=C(Cl)C=C1C(=O)N[C@H](C1C=CC(C(=O)O)=CC=1)C
InChi Key	MWBNCZHVEXULBD-ZDUSSCGKSA-N
InChi Code	InChI=1S/C22H17ClFNO4/c1-13(14-2-4-15(5-3-14)22(27)28)25-21(26)19-12-16(23)6-11-20(19)29-18-9-7-17(24)8-10-18/h2-13H,1H3,(H,25,26)(H,27,28)/t13-/m0/s1
Chemical Name	4-[(1S)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]benzoic acid
Synonyms	CJ-042794; CJ-042794; CJ-042794; RQ-00015986; RQ-15986
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	EP ( EC50 = 10 nM )
ln Vitro	CJ-042794 (CJ-042794, 0.3-5000 nM; 10 min; hEP4/HEK293 cells) shows concentration-dependent inhibition of the PGE2-induced elevation of cAMP with a pIC50 value of 7.5[1]. CJ-042794 (3-3000 nM; 24 h) CJ-042794 reverses the inhibitory effects of PGE2 (10 nM) on the LPS-induced production of TNFα in human whole blood (HWB), with a pIC50 value of 6.4 in a concentration-dependent manner[1].
ln Vivo	CJ-042794 (CJ-042794; 0.3-3 mg/kg; i.d.; once) inhibits AE1-329'sHCO3stimulatory action in the duodenum[1]. CJ-042794 (30 and 50 mg/kg; p.o.; once) has no gastric ulcerogenic response and does not harm the gastric mucosa of normal rats in response to cold-restraint stress[1]. CJ-042794 (30 and 50 mg/kg; p.o.; once) does not harm helper arthritis rats' stomachs or small intestines[1]. CJ-042794 (3-45 mg/kg; p.o.; twice daily for 14 d; Sprague-Dawley rats) promotes spontaneous healing of gastric ulcers[1]. The repeated administration of CJ-042794 (10 mg/kg; p.o.; daily, for 7 d) inhibits the healing process of chronic gastric ulcers by downregulating the expression of vascular endothelial growth factor in the ulcerated mucosa[1].
Animal Protocol	Male Sprague-Dawley rats (200-230 g) 0.3, 1, and 3 mg/kg intradermal injection; once
References	[1]. In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist. Life Sci. 2008 Jan 16;82(3-4):226-32. [2]. Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido)ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa. J Pharmacol Exp Ther. 2007 Sep;322(3):903-12.
Additional Infomation	Benzoic acid, 4-[(1s)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]- is an aromatic ether.

Solubility Data

Solubility (In Vitro)

DMSO: ≥ 28 mg/mL (~67.7 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (6.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.04 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.4165 mL	12.0823 mL	24.1645 mL
	5 mM	0.4833 mL	2.4165 mL	4.8329 mL
	10 mM	0.2416 mL	1.2082 mL	2.4165 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.